Eradication of poliomyelitis

The other important issue with polio vaccine is raised in the Comment from New Zealand (July 30, p 351):4 the choice between (live) oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV). But the replacement of OPV with IPV should not be as controversial as Caiman MacLennan and Jenny...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2005-10, Vol.366 (9492), p.1163-1163
Main Author: Jacob John, T
Format: Article
Language:English
Subjects:
Child, Preschool
Female
Humans
Immunization Programs
Poliomyelitis - etiology
Poliomyelitis - prevention & control
Poliomyelitis - virology
Poliovirus - classification
Poliovirus - isolation & purification
Poliovirus Vaccine, Oral - adverse effects
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The other important issue with polio vaccine is raised in the Comment from New Zealand (July 30, p 351):4 the choice between (live) oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV). But the replacement of OPV with IPV should not be as controversial as Caiman MacLennan and Jenny MacLennan imply. Not only is IPV safer than OPV: it is more immunogenic2 and associated with reduced delivery cost.5 Whereas two or three doses of enhanced-potency IPV gave excellent protection in India and Senegal, it took a mean of 10 doses of OPV per child, over a period of 8-9 years, to interrupt transmission of the virus in South America.2
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(05)67476-4